AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17117227
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone plus intrapericardial placebo
Trial: 14664167
Drug: Arifon retard
RxNorm normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arifon retard monotherapy
Trial: 14664167
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of arifon retard and climonorm
Trial: 14664167
Drug: Arifon retard
RxNorm normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arifon retard in combination with climonorm
Trial: 10655249
Drug: Fasting insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fasting insulin levels in women
Trial: 10655249
Drug: Fasting insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fasting insulin and C-peptide in men
Trial: 1338389
Drug: Fluoxetine 60
RxNorm normalized name: fluoxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 60 mg once daily for 24 weeks
Trial: 6711261
Drug: suxamethonium 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suxamethonium 0.1 mg/kg
Trial: 27322462
Drug: 5mg finasteride
RxNorm normalized name: finasteride 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg finasteride daily for 4-6 weeks
Trial: 20416389
Drug: Inhaled magnesium
RxNorm normalized name: Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled magnesium sulfate (333 mg in 3 ml solution)
Trial: 20416389
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 ml isotonic saline solution with albuterol and ipratropium)
Trial: 17700289
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination of M‐FDT with the latter pair of criteria
Trial: 10730980
Drug: PGF2alpha treatment
RxNorm normalized name: PGF2alpha THAM
DrugBank: Dinoprost tromethamine (DB01160)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGF2alpha treatment
Trial: 10730980
Drug: Progesterone treatment
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone treatment (100 mg daily from Days 10 to 30)
Trial: 8803525
Drug: S-1452 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1452 (50 mg) with food
Trial: 8803525
Drug: S-1452 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1452 (50 mg) without food
Trial: 8803525
Drug: S-1452 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1452 (50 mg) with food and without food
Trial: 28489511
Drug: Celecoxib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (400 mg twice per day)
Trial: 23187951
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g of β‐glucans daily for 8 weeks
Trial: 21489769
Drug: Bupivacaine 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.625 mg/mL with epinephrine 5 μg/mL at 10 mL/hr
Trial: 21489769
Drug: Bupivacaine 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.625 mg/mL at 10 mL/hr
Trial: 19069713
Drug: Perineural injection
RxNorm normalized name: ROPIVACAINE HYDROCHLORIDE 2 mg in 1 mL PERINEURAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perineural injection of 1 ml of betamethasone after surgical decompression
Trial: 3913752
Drug: L-5-Hydroxytryptophan (L-5-HTP)
RxNorm normalized name: L-5-HTP
DrugBank: Oxitriptan (DB02959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-5-Hydroxytryptophan (L-5-HTP)
Trial: 29533686
Drug: MIES (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIES (all doses)
Trial: 30427213
Drug: Standard cognitive‐behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cognitive‐behavioral therapy (CBT)
Trial: 26970721
Drug: LAM-guided anti-tuberculosis
RxNorm normalized name: Mycobacterium tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAM-guided anti-tuberculosis treatment initiation
Trial: 24524676
Drug: CNS stimulants
RxNorm normalized name: CNS STIMULANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNS stimulants (methylphenidate or dexamphetamine)
Trial: 29154553
Drug: Female‐Specific Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Female‐Specific Cognitive Behavioral Therapy (FS‐CBT)
Trial: 30831454
Drug: Paliperidone-extended release
RxNorm normalized name: paliperidone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paliperidone-extended release formulation
Trial: 27609242
Drug: Citalopram treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram treatment (open group)
Trial: 27609242
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (placebo-controlled group)
Trial: 19216655
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (10 sessions)
Trial: 17990836
Drug: Long-acting inhaled
RxNorm normalized name: Sinex Long-Acting Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting inhaled anticholinergics
Trial: 17990836
Drug: Long-acting inhaled
RxNorm normalized name: Sinex Long-Acting Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting inhaled anticholinergics, inhaled corticosteroids, possibly long-acting beta2 agonist or mucolytics
Trial: 17990836
Drug: Short-acting beta2
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting beta2 agonists or combination anticholinergics with a short-acting beta2 agonist
Trial: 23668549
Drug: Bevacizumab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (5 mg/kg)
Trial: 7658874
Drug: Bosentan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan (100 mg followed after 60 min by 200 mg)
Trial: 1089090
Drug: Marijuana smoking
RxNorm normalized name: Picea mariana resin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marijuana smoking (12 mg delta9‐tetrahydrocannabinol)
Trial: 22689129
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of POMx
Trial: 22689129
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g of POMx
Trial: 18804874
Drug: Once weekly
RxNorm normalized name: Actonel 35 4-Week Once Weekly Dosepack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly water exercise (60 minutes, 1 session per week for 2 years)
Trial: 18804874
Drug: Twice weekly
RxNorm normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly water exercise (60 minutes, 2 sessions per week for 2 years)
Trial: 10370793
Drug: Paclitaxel 200
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 200 mg/m2 by three-hour infusion on day 1 and gemcitabine 1100 mg/m2 over 30 min on days 1 and 8, repeated every three weeks for six cycles.
Trial: 93982
Drug: Crossover therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover therapy with 5-FU alone
Trial: 19390239
Drug: Pranlukast hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pranlukast hydrate plus oral mequitazine
Trial: 19390239
Drug: Fexofenadine hydrochloride
RxNorm normalized name: Fexofenadine Hydrochloride
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine hydrochloride plus oral mequitazine
Trial: 14742342
Drug: Bolus dose
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus dose of rocuronium
Trial: 8557012
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of rocuronium
Trial: 9164208
Drug: Paclitaxel 150
RxNorm normalized name: paclitaxel 150 MG per 25 ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel 150 mg/m2
Trial: 9164208
Drug: Paclitaxel 275
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 275 mg/m2
Trial: 27108672
Drug: lurasidone 40
RxNorm normalized name: lurasidone 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lurasidone 40 mg
Trial: 25470096
Drug: RUL brief‐pulse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RUL brief‐pulse ECT (mean dose = 233.3 mC)
Trial: 25470096
Drug: Algorithm‐based pharmacologic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algorithm‐based pharmacologic treatment (APT)
Trial: 22826463
Drug: [(14)C]β‐sitosterol administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [(14)C]β‐sitosterol administered orally
Trial: 22826463
Drug: [(14)C]β‐sitosterol administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [(14)C]β‐sitosterol administered intravenously
Trial: 11910264
Drug: 5-HTP 200
RxNorm normalized name: 5-HTP 200 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-HTP 200 mg
Trial: 12534636
Drug: Ropivacaine 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 50 mg, 100 mg, and 200 mg base as 20-ml gel enemas
Trial: 1621138
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment (classical tranquilizers)
Trial: 30700475
Drug: Standard sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard sequential chemoradiotherapy schedule of 55 Gy in 20 fractions over 4 weeks
Trial: 30700475
Drug: Experimental radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental radiotherapy schedules (4 separate dose escalation accelerated radiotherapy schedules)
Trial: 27362935
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of anti-CD138-IFNα14 and bortezomib
Trial: 17372173
Drug: hs-CRP levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-CRP levels 1 to 3 mg/L
Trial: 17372173
Drug: hs-CRP levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-CRP levels >3 mg/L
Trial: 776350
Drug: Methyldopa 750
RxNorm normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methyldopa 750 mg/day combined with propranolol 240 mg/day
Trial: 776350
Drug: Methyldopa 750
RxNorm normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methyldopa 750 mg/day combined with practolol 600 mg/day
Trial: 776350
Drug: Practolol 600
RxNorm normalized name: (±)-practolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Practolol 600 mg/day
Trial: 30905211
Drug: ICS/LABA treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICS/LABA treatment
Trial: 25875383
Drug: Sublingual nitroglycerin
RxNorm normalized name: nitroglycerin Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual nitroglycerin (NTG) doses of 10, 20, 30, and 40 μg
Trial: 21865363
Drug: Low-dose pioglitazone-flutamide-metformin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose pioglitazone-flutamide-metformin (PioFluMet)
Trial: 19262436
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (1.25 mg/0.05 mL) before PRP
Trial: 22809091
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination brimonidine-timolol (FCBT)
Trial: 17407624
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination dorzolamide-timolol (FCDT)
Trial: 9711427
Drug: Gemfibrozil therapy
RxNorm normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gemfibrozil therapy for 12 weeks
Trial: 8040675
Drug: Tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg/d orally
Trial: 8040675
Drug: MPA 1
RxNorm normalized name: Fycompa 10mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPA 1 g/d orally
Trial: 2689895
Drug: Substitution therapy
RxNorm normalized name: hydroxypropyl cellulose, low substituted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substitution therapy with thyroxine
Trial: 791472
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of fluorouracil, methyl‐CCNU, and vincristine
Trial: 24632426
Drug: Selective pulmonary
RxNorm normalized name: Lobaria pulmonaria extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective pulmonary perfusion (sPP) with venous blood at 2°C, 4 l
Trial: 17921377
Drug: Glucose and
RxNorm normalized name: Glucose and treacle only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose and 2.4 g amino acid kg(‐1) d(‐1)
Trial: 16076947
Drug: Pegvisomant (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegvisomant (10 mg/d)
Trial: 11966672
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg moclobemide coadministration with 40 mg omeprazole
Trial: 11966672
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg omeprazole alone
Trial: 7137540
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg bupivacaine
Trial: 7137540
Drug: 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg prilocaine
Trial: 24665578
Drug: Histamine concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine concentrations of 1 mg/mL
Trial: 24665578
Drug: Histamine concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine concentrations of less than 2 mg/mL
Trial: 22926408
Drug: Epidural fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural fentanyl (100-μg bolus)
Trial: 15657908
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MRSI and MRI data
Trial: 9468365
Drug: Ritonavir, lamivudine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir, lamivudine, and zidovudine (triple combination treatment)
Trial: 9468365
Drug: Ritonavir monotherapy
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir monotherapy (initial treatment before adding lamivudine and zidovudine)
Trial: 8521898
Drug: Intravenous thyrotropin-releasing
RxNorm normalized name: thyrotropin-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thyrotropin-releasing hormone (TRH) 200 micrograms
Trial: 2222550
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release propranolol (160 mg)
Trial: 2222550
Drug: Conventional propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional propranolol tablet (80 mg)
Trial: 2222550
Drug: Conventional propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional propranolol tablet
Trial: 29882696
Drug: Propofol post-conditioning
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol post-conditioning (Cp 1.2 µg/mL)
Trial: 29098740
Drug: Noncontact low-frequency
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noncontact low-frequency ultrasound (NLFU) treatment
Trial: 15694559
Drug: Tiagabine b.i.d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine b.i.d. (twice daily)
Trial: 15694559
Drug: Tiagabine t.i.d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine t.i.d. (three times daily)
Trial: 12413995
Drug: Standard long
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard long GnRH agonist (GnRH-a)-gonadotropin stimulation
Trial: 9856877
Drug: Epsilon‐aminocaproic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epsilon‐aminocaproic acid (EACA) 100 mg/kg at cannulation followed by 25 mg/kg/h for 72 hours
Trial: 2146067
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of isophane (NPH) insulin
Trial: 2146067
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of isophane (NPH) insulin
Trial: 147656
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive containing cyproterone acetate
Trial: 147656
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive containing d-norgestrel
Trial: 147656
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (without hormonal medication)
Trial: 12469457
Drug: Parenteral nutritional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutritional support (Group B)
Trial: 19741029
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) intervention (n = 21)
Trial: 28490349
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) intervention
Trial: 15667429
Drug: Olanzapine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (mean dosage 16.2 +/- 4.8 mg/day)
Trial: 15667429
Drug: Clozapine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine (mean dosage 209 +/- 91 mg/day)
Trial: 9934940
Drug: Intranasal vasopressin
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal vasopressin (20 IU before bedtime and after awakening)
Trial: 619934
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release tablet containing 300 mg of papaverine hydrochloride
Trial: 619934
Drug: Capsule containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule containing 300 mg of papaverine hydrochloride
Trial: 17722957
Drug: 3-week cycles
RxNorm normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-week cycles of intravenous (IV) docetaxel plus cisplatin and fluorouracil (5-fluorouracil)
Trial: 16252573
Drug: Rivastigmine 3‐6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine 3‐6 mg twice daily for 20 weeks
Trial: 11697709
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (0.3 g/kg in a 4-week cycle until the 28th to 32nd week of gestation), aspirin (100 mg/d), and certoparin (3,000 anti-Xa U/d)
Trial: 11697709
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (aspirin and low‐molecular‐weight heparin)
Trial: 7998586
Drug: rilmenidine 1-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rilmenidine 1-2 mg/day (n = 46)
Trial: 7998586
Drug: Hydrochlorothiazide (HCZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCZ) 25-50 mg/day (n = 42)
Trial: 3056208
Drug: Intravenous ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ceftriaxone (1%) at induction of anaesthesia
Trial: 28430748
Drug: Vero cell‐derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vero cell‐derived inactivated JE virus vaccine (IXIARO), 0.25 mL for <3 years and 0.5 mL for ≥3 years, administered 28 days apart
Trial: 25881753
Drug: Pomaglumetad methionil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomaglumetad methionil 400 mg
Trial: 20027348
Drug: Anaferon (pediatric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anaferon (pediatric formulation) as a component of complex therapy
Trial: 16495392
Drug: Glucosamine 1500
RxNorm normalized name: glucosamine 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucosamine 1500 mg daily
Trial: 16495392
Drug: Chondroitin sulfate
RxNorm normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chondroitin sulfate 1200 mg daily
Trial: 16495392
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (glucosamine and chondroitin sulfate) in moderate-to-severe pain